Reducing Benzodiazepine Use in the Treatment of Anxiety in a Community Mental Health Setting by Mink, Gayle M
Bellarmine University 
ScholarWorks@Bellarmine 
Graduate Theses, Dissertations, and Capstones Graduate Research 
12-2-2016 
Reducing Benzodiazepine Use in the Treatment of Anxiety in a 
Community Mental Health Setting 
Gayle M. Mink 
Bellarmine University\, gayle.mink@centerstone.org 
Follow this and additional works at: https://scholarworks.bellarmine.edu/tdc 
 Part of the Psychiatric and Mental Health Nursing Commons 
Recommended Citation 
Mink, Gayle M., "Reducing Benzodiazepine Use in the Treatment of Anxiety in a Community Mental Health 
Setting" (2016). Graduate Theses, Dissertations, and Capstones. 34. 
https://scholarworks.bellarmine.edu/tdc/34 
This Capstone is brought to you for free and open access by the Graduate Research at ScholarWorks@Bellarmine. 
It has been accepted for inclusion in Graduate Theses, Dissertations, and Capstones by an authorized 
administrator of ScholarWorks@Bellarmine. For more information, please contact jstemmer@bellarmine.edu, 
kpeers@bellarmine.edu. 









Reducing Benzodiazepine Use in the Treatment of Anxiety in a Community Mental Health 
Setting 











Reducing Benzodiazepine Use in the Treatment of Anxiety in a Community Mental Health 
Setting 
Background and Significance 
Anxiety disorders are among the most common mental health disorders in the United 
States according to the Substance Abuse and Mental Health Administration Services 
(SAMHSA), affecting nearly 18% of the adult population annually (SAMHSA, 2013). 
Modalities for the treatment of anxiety disorders shifted in the late 1980s and early 1990s 
because of concerns in the medical community regarding the risks of abuse and dependence 
engendered by the long-term use of benzodiazepines (Smith & Tett, 2010). The most common 
treatment approaches have included a combination of non-pharmacological interventions and 
medication approaches as endorsed in the United Kingdom in the seminal work of Dr. C. 
Heather Ashton (Ashton, 1994) and mirrored by the American Psychiatric Association in its own 
seminal work in the United States (APA, 1990.) 
A consensus report was adopted by the American Psychiatric Association (APA) to limit 
the use of these agents and best practice models were adapted to guide prescribers (APA, 1990). 
These best practices included limiting benzodiazepines to short-term use due to their risk of 
tolerance and dependence (NICE, 2011). The use of benzodiazepines, according to a best 
practices model, should be limited to crisis intervention or to assist in the abatement of the most 
severe anxiety and panic symptoms, with the intent to concurrently prepare the patient for the 
work of learning to manage anxiety and panic (Ashton, 1994).  
It is an accepted tenet that the extended use of these agents to treat anxiety encourages 
abuse and dependence and compromises the sobriety of individuals recovering from alcohol and 
illicit drug dependencies (APA, 1990; Ashton, 1994). Additional risks inherent in the use of 
benzodiazepines occur when the drug is abruptly withdrawn or not available to an individual 
who has developed dependence include seizure activity, withdrawal symptoms, rebound anxiety 
and rebound hypertension (APA, 1990, p. 35). Recent research has also implicated the use of 
benzodiazepines in increased incidences of dementia (de Gage, et al. 2012). 
Benzodiazepines continue to be prescribed often: 112.8 million benzodiazepine 
prescriptions were filled in 2007 (Cascade  & Kaskali,, 2008). Data from 1987 indicates that this 
number was 10.9 million (Olfson & Pincus, 1994). According to the Centers for Disease Control 
(CDC) death rates attributable to overdoses more than tripled since 1990 (CDC, 2011). While 
prescription pain medications, primarily opiates, are responsible for three out of four prescription 
drug-related deaths, over half of those deaths involve concomitant use of benzodiazepines, 
cocaine and alcohol (CDC, 2011). The American Academy of Pain Medicine (AAPM) recently 
released a report based on CDC data indicating that 30% of prescription drug deaths result from 
an opioid-benzodiazepine combination (AAPM, 2013).  The study by Bachuber, et al. (2016) 
noted that overdose deaths from benzodiazepines increased from .58 per 100,000 in 1996 to 3.07 
per 100,000 in 2013. 
 For the past twenty years, the standard of care for the treatment of anxiety 
disorders has consisted of psychotherapeutic modalities: cognitive-behavioral therapy (CBT,) 
mindfulness and relaxation techniques, as well as other non-medication-focused treatments. The 
first-line approach, during this same time span, has also consisted of medications that target 
neurotransmitters believed to play major roles in the mediation of symptoms associated with 
anxiety disorders; these medications have included Selective Serotonin Re-uptake Inhibitors 
(SSRIs,) Serotonin and norepinephrine re-uptake inhibitors (SNRIs,) GABAergic agents and 
other non-benzodiazepine anxiolytics.  
In spite of this standard of practice (Magellan, 2012), the use of benzodiazepines has not 
significantly decreased. A recent study conducted by Bachhuber, Hennesey, Cunningham, and 
Starrels (2016), using data from the CDC, concluded that between 1996 and 2013, the number of  
filled prescriptions for benzodiazepines, in the adult population, rose from 4.1% to 5.6%.  If 
actual practice deviates from established standards of practice, as the data supports, (Sanyal, 
Asbridge, Kisely, Sketris & Andreou, 2011), the reasons for this deviation must be explored and 
an attempt made to determine if there is a valid reason to alter the best practices approach. 
Conversely, if this deviation from care continues to exact the price of poor outcomes and 
abuse/dependence that has previously been established, practitioners must be encouraged to 
conform to these best practices. 
Purpose 
 The purpose of this project is to develop and implement an evidence based pilot program 
that uses an internet-based, cognitive-behavioral program to successfully wean clients using 
benzodiazepines for anxiety disorders with minimal to no perceived participant distress and to 
reduce the risk of dependence, addiction, and overdose with these agents. 
Literature Review 
An initial search was conducted using the standard CINAHL nursing database. This 
initial search netted few germane research articles. Therefore, the search was broadened to 
include the following journal databases: Academic Search Premier; CINAHL, Health and 
Psychosocial Instruments, Health Source - Consumer Edition, Health Source: Nursing/Academic 
Edition, MEDLINE, PsycARTICLES, Psychology and Behavioral Sciences Collection and 
PsycINFO.  The Substance Abuse and Mental Health Services (SAMHSA) website was also 
searched for relevant scholarly articles, and resources. 
 Because the topic of interest included best practices models and practice guidelines, the 
following web-sites were also searched: National Institute of Health (NIH), National Institute of 
Mental Health (NIMH), American Psychiatric Nurses Association (APNA) policy papers, 
American Medical Association (AMA) policy papers, Kentucky Board of Nursing (KBN), and 
the National Guideline Clearinghouse. 
 Throughout the search, several search terms were used. Initially, basic terms such as 
“anxiety disorders”, “benzodiazepines”, “treatment of anxiety” were used. It was quickly 
apparent that these search terms were often too vague or too broad to garner relevant research 
studies. Therefore, numerous journal articles were reviewed and other terminology was used to 
refine the previous searches. Effective search terms included: “treatment of anxiety disorders in 
PTSD”, “cognitive-behavioral therapy”, and “mindfulness” among many others. The initial 
literature search was halted when saturation was reached. 
 Thirty-eight articles were determined to be relevant to this review. Of those articles, 
twelve contained randomized-controlled trials (RCTs). Of the studies that included RCTs, nine 
of those were integrated studies, consisting of quantitative and qualitative data. Because of the 
subjective nature of outcomes most commonly measured in psychiatric research, integrated 
studies often capture data that is difficult to quantify. Four of the studies included were 
descriptive studies and six were systematic literature reviews. Three articles meeting criteria for 
inclusion in this review were clinical guidelines. Also included in this review were two focus 
groups study, an expert opinion paper, four post-hoc integrated studies, one criterion-standard 
study, and five descriptive studies. 
 The seminal work from the APA (1990) identified the inherent problems of addiction and 
dependence with long-term benzodiazepines and recommended that physicians alter their 
practices to consider the use of talk therapies as first-line modalities of care for the treatment of 
anxiety.  It declines to make specific recommendations for time limits on the prescribing of 
benzodiazepines, possibly due to its reluctance to hinder the judgment of the individual 
physician’s judgment.  There are no follow-up publications or white papers by the APA that have 
addressed this practice standard since the 1990 publication. Another seminal work, this time 
from Great Britain, The Ashton Report  (Ashton, 1994) set forth similar practice guidelines for 
psychiatrists, urging limited use of benzodiazepines and encouraging providers to employ more 
talk therapies as first-line courses of treatment for anxiety. Magellan (2012) published clinical 
guidelines promoting talk therapies such as CBT as the first line of treatment for individuals with 
anxiety disorders. It recommends talk therapies plus medications as first line treatments, but 
specifically attempts to dissuade providers from including long-term benzodiazepines within the 
definitions of first line medications.  
 Gosselin, Morin, Dugas, & Baillargeon (2006) demonstrated the positive benefits of CBT 
in their Canadian study. These researchers gathered a convenience sample, later randomized to 
groups, through media ads. The initial respondents (N=273) were screened for study inclusion. 
The criteria for study inclusion was based on individuals meeting the criteria for Generalized 
Anxiety Disorder, currently prescribed a benzodiazepine and expressing a willingness to 
discontinue treatment with those agents (N= 61). These participants were randomized to two 
groups: one group received usual care (n= 30) and the other group received CBT (n= 31). At the 
end of the three month study, 74% of the group who received CBT had discontinued 
benzodiazepines versus 36% in the group receiving usual care.  These findings supported the 
hypothesis that the addition of CBT to treatment for people with anxiety can increase the ability 
to wean them from these agents. Follow up anxiety screening using  the Worry and Anxiety 
Questionnaire demonstrated continued benefits of CBT at the 6- and 12-month assessment 
points.   
 In an effort to locate existing research on current policy, laws, and statistical information 
related to the prescribing of controlled substances, specifically benzodiazepines, a literature 
search was pursued using Google Scholar, Google, and National Institute for Mental Health 
(NIMH) databases. This search netted sixteen germane articles. Of these sixteen articles, two 
were time series analyses of prescribing habits (Cunningham, Hanley, & Morgan, 2010; 
Dormuth, Miller, Huang, Mamdani., & Juurlink,  2012).One study was a prospective analysis. 
The remaining thirteen articles were white papers, statistical reports and laws pertaining to the 
prescribing of controlled substances in the United States, Great Britain, Ireland, Canada and 
Australia. Practice guidelines and statistical data from the World Health Organization (WHO) 
were also obtained.   
 Figures released by the Kentucky Injury Prevention and Research Center (2014) report 
that the number of overdose-related hospitalizations involving benzodiazepines in Kentucky in 
2000 was 793; in 2013 that number was 1,686 (Svetla, Bunn, & Lambert, 2014). The cost of care 
for all drug overdose hospitalizations (of which benzodiazepines are the singular cause or 
contributory) rose from $21.1 million in 2000 to $129.3 million in 2012; total days of 
hospitalization days for overdoses in Kentucky rose from 10,385  in 2000 to 21,344 in 2012 
(Svetla   et al., 2014). The 2013 report issued by Trust for America's Health  (TFAH) found that 
Kentucky ranks third in the nation in drug overdose mortality  and that a large proportion of 
those deaths are prescription drug related (TFAH, 2013). The same report, however, endorsed 
Kentucky as one of the leading states in its corrective planning to curb those deaths, including 
increased education for prescribers, increased real-time access to a controlled drug monitoring 
program and efforts to educate the public on the dangers of misuse of prescription drugs (Trust 
for America's Health, 2013). 
 In response to increasing deaths associated with prescription drug overdoses, primarily 
opiates but also benzodiazepine-only or combination overdoses that include benzodiazepines, the 
Kentucky Legislature adopted House Bill 1 (now KRS 218A) to hold prescribers more 
accountable for the prescribing of the agents (as well as psychostimulants) in 2013. Its purpose 
was to outline the requirements of prescribers to provide minimal assessment, documentation of 
need, review of the state’s controlled reporting system [KASPER] and engaging in education 
with clients that is documented by written contracts between the patient and the prescriber, 
signifying the patient is aware of the conditions under which these controlled agents would be 
prescribed (Cohron, 2014; Parton, 2012).   
Theoretical Framework 
 The recovery model provides the theoretical underpinning of this project (Anthony, 
1993). The recovery model developed out of the “survivor” movement of the 1970s when a 
number of people with mental illnesses began to write about their experiences with 
institutionalized (whether inpatient or community) psychiatric care. These pioneers considered 
themselves survivors and ex-patients as they pulled away from traditional, pharmacological, and 
restrictive treatments. Initially, there was much opposition between these consumers and the 
professionals who considered their labors to be minimized at best and vilified at the worst. Over 
the ensuing decades, these sides have come together in a less oppositional manner and have, over 
time, contributed to a body of knowledge that has formalized the recovery model as a conceptual 
framework. 
            The core belief of the recovery model is that people get better. Their illness is a reality 
and has changed their lives, forever. People move on and the illness does not have to remain a 
focus of their entire lives (Anthony, 1993). It is not a necessary result of mental illness to lose all 
the roles that people have achieved or strive to achieve. Recovery can concretely be interpreted 
as recovering valued roles: worker, student, parent, significant other, sibling, author, and so on. 
Any dreams that a person without a mental illness is entitled to, so is a person with a mental 
illness. As a result of the “take back our lives” focus of the originators of the recovery model, 
stakeholders in mental health (providers and consumers alike) have adopted a person-centered, 
respectful stance with those individuals who must deal with a mental illness that impacts all 
areas of their lives. A basic tenet of the recovery model is responsibility for self: “The recovery 
model emphasizes that responsibility for and control of the recovery process must be given in 
large part to the person who has the condition.” (Frese, Stanley, Kress & Vogel-Scibilia, 2001). 
Mental health providers have gradually come to incorporate this model and its philosophy into 
day-to-day care, treatment planning and goal-setting. 
Best practices treatment for anxiety, such as cognitive-behavioral therapy, are consistent 
with the recovery model. In CBT, the person is taught the tools to rethink, reframe and thus 
change their own behaviors in coping with anxiety- provoking thoughts and circumstances. Once 
taught, these tools cannot be un-taught and remain lifelong skills for the person. Conversely, the 
use of benzodiazepines inherently requires a consistent dependence on a prescriber so that the 
prescriber can provide the “tool” to decrease anxiety in the form of a pill; and with 
benzodiazepines, the “choice” is much reduced for the consumer by the very nature of their 
mechanisms of action.  
Methods and Procedures 
 Design. This was an evidence-based pilot project using a one-group, pre-test, post-test 
model.  
 Setting. This pilot project was conducted in an urban community mental health center in 
the southeastern United States that serves over 1,900 clients. This center serves adults with a full 
complement of mental illnesses, intellectual disabilities, substance use disorders, and other 
emotional and behavioral disturbances.  
Population. The project coordinator (DNP student) identified three colleagues who 
voiced a willingness to participate in the recruitment of participants from their caseload of 
patients currently receiving benzodiazepines. A search was conducted using the agency’s 
electronic prescribing software to obtain a list of active prescriptions for benzodiazepines 
prescribed by the three colleagues as well as the project coordinator. This resulted in a list of 
over 60 people. From that list, only individuals who met the criteria for the project were 
included. Excluded individuals were those with developmental disabilities, traumatic brain 
injuries and dementia. The rationale for this exclusion is the presumption that there may be 
limited ability on the part of these individuals to successfully access and retain the information 
available in the web-based CBT program. The resulting number of potential participants was 38. 
All potential participants were invited into the project by the project coordinator, either in 
person or through a letter of invitation sent in advance of their next scheduled appointment with 
their respective prescriber. In the letter, a brief introduction of information was made regarding 
the intended project and an invitation to discuss this opportunity with his or her prescriber at the 
next visit with the prescriber. The prescribers were asked by the project coordinator to follow up 
with these clients at their next scheduled visit to discuss the project further and to engage the 
project coordinator for further instruction if the patient evidenced any interest in engaging in the 
project.  
The time period for enrolling participants in the pilot project was from January 1, 2016 to 
March 31, 2016. At the end of the enrollment period, the total number of patients who were 
willing to participate was seven. All participants were clients of the project coordinator. While 
the other involved prescribers informally informed the project coordinator that he or she had 
heard affirmative responses from “some’ of their patients none, ultimately, agreed to engage in 
the pilot.  
Sample. This was a convenience sample of seven clients. All were over 18 years old and 
had been prescribed long-term benzodiazepines. For the purposes of this project, long-term was 
defined as greater than four months.  
 Data Collection. Data was collected documenting the dosages of prescribed 
benzodiazepines for each participant at the beginning and end of this project to assess any 
decrease in usage. Data was collected to reflect if each participant used the web-based program 
during the project. Data was collected in the form of pre-project levels of anxiety using the 
GAD-7 at the beginning of participation in the project and at the end of participation. 
Additionally, the use of individual or group therapy was controlled for by collecting data 
regarding each participant’s pre-project participation in therapy and any participation in therapy 
during the project and any differences were noted. Demographic data was gathered for 
participants and non-participants in the project for further analysis post-project. 
Instrument. The Generalized Anxiety Disorder scale-7, GAD-7, (Appendix A) was used 
as the measurement tool to assess levels of anxiety in participants. The GAD-7 was developed in 
the mid-1990s as a brief screening tool for self-assessment of anxiety symptoms. It has been in 
common use in behavioral health services since and has been used extensively in clinical practice 
as well as for study purposes (Kroenke, Spitzer, Williams & Lowe, 2007). In one large-scale 
study, the originators of the GAD-7 tested the instrument within a population of greater than 
2700 patients. This study determined that the GAD-7 was an efficient and effective screening 
tool with a specificity of 82% and a sensitivity of 89% and was determined to have good 
reliability and procedural validity (Spitzer, Kroenke, Williams & Löwe, 2006). 
 Intervention. In an effort to minimize the risk of increased anxiety during this project, all 
participants were given written and verbal information to engage in a self-help web-based CBT 
program entitled “Living Life to the Full. (Appendix B.) This web-based program was developed 
by Dr. Chris Williams, a psychiatrist at the University of Glasgow. Each participant was also 
offered on-site access to a computer and one-on-one assistance to activate the program for their 
use.  
 Procedure. At entry into the project, each participant’s daily dosage of benzodiazepine 
was recorded by the project coordinator.  Each patient was administered the GAD-7 at the entry 
into the project to assess baseline anxiety. Each patient was provided with the verbal and written 
directions to access the web-based, self-help program based on cognitive-behavioral concepts 
(“Living Life to the Full.”). Each patient’s benzodiazepine dose was reduced by no more than 
one-half pill within their dosage range of every month until the project was completed (i.e., if the 
patient’s current regimen was 1 mg of clonazepam twice daily, the dosage was reduced to 0.5 mg 
in the morning and 1mg in the evening for a month at least, then reduced to 0.5 mg twice daily 
for a month, and so on.). At every med check, the prescriber monitored the client’s subjective 
experience and if the client was actively participating on her/his own in the web-based program. 
At each med check the prescriber encouraged the use of web-based participation, offered support 
and any needed additional assistance (i.e. help via Peer Support Specialists, therapists, case 
managers). Once each participant’s involvement in the project concluded, the GAD-7 was 
administered and pre- and post-project results were compared.  
Stakeholders 
 There were numerous stakeholders involved in this project. The implementation of this 
project had a direct impact on prescribers’ practice; each was asked to enroll clients who met 
inclusion criteria. The time involved in adding this component to the prescribers’ already-full 
routine to reach potential participants was not inconsiderable. Additionally, time within 
scheduled sessions was needed to allow the prescribers to explain the risks of long-term 
benzodiazepine use and the process of weaning and its implications. Another stakeholder in this 
process was the patient. He or she was asked to consider alternate therapies for the treatment of 
anxiety symptoms, not just benzodiazepines. The changes asked of the client impacted time in 
session, it challenged the way the client regarded benzodiazepine dependence on his/her life, and 
the potentially decreased amount of time spent, overall, dealing with the mental health system 
having discarded the dependence on prescribers’ discretionary provision of benzodiazepines.   
 Therapists, case managers and peer support specialists comprise another portion of 
stakeholders in that they were asked to assist clients in addressing their anxiety via the use of the 
CBT program. While none of the eventual participants engaged in the offered CBT program, 
these clinicians were still asked to take the time to be prepared for the possibility The business 
staff had a stake in this project in that there were variations in their time spent assisting clients in 
accessing benzodiazepine prescriptions and trouble-shooting problems with these agents.
 Insurance companies and other third-party payers have a stake in this project in that they 
provide the means by which clients afford this care. A change in treatment that is less prescriber-
dependent and allows for self-help by the patient potentially reduces the cost of health care. 
Families and support networks comprise another portion of the stakeholders for this project; 
more effective symptom treatment for the patient (their significant other) may convey limited 
burden to these individuals as well.  A final stakeholder is the community mental health center 
(CMHC) itself. Reducing prescriber-dependent treatment by the implementation of a web-based, 
self-help program may reduce the number of visits to prescribers and thus reduce reimbursement. 
Conversely, for over-burdened CMHCs, this could translate into more available time for other 
clients with more complex and more severe mental illnesses. The CMHC may also need to 
change some of its policies and procedures to align with best practices in the treatment of clients 
with anxiety symptoms. 
Responsibilities of the Team 
 Project coordinator (DNP Student):  Designed and implemented the project; shared with  
other prescribers a  project overview, its goals, any time limits, the intervention (web-based CBT 
program)—attempted to ensuring access/buy-in to program, ongoing encouragement to use  
web-based program themselves and with clients. Administered GAD-7 to participants at 
beginning and end of project participation, collected data, served as “problem-solver” throughout 
project, interpreted data, ensured confidentiality and enrolled participants. 
 Peer Support Specialists: Remained available to assist clients in accessing computer, if 
needed, via on-site computer lab. They also were available to assist clients with any learning 
needs to ensure adequate understanding and utilization of web-site. 
 Therapists and Case Managers: They were made aware of clients that were in the process 
of tapering from benzodiazepines and provided additional support as needed to those clients. 
Business Staff: Assisted in the monitoring of benzodiazepine use by accessing 
KASPER/INSPECT/electronic prescribing programs and forwarded this info to the project 
coordinator (DNP student) for data collection when requested. 
Data Collection Plan and Tools 
 This project used two author-produced data collection. The Project Demographics chart 
for participants (Appendix C) was used to gather demographic data on all active participants in 
the project as well documentation of benzodiazepine dosage, pre- and post-project, use of the 
CBT web-based program and GAD-7 scores, pre- and post-project. The second tool used was the 
Project Demographics for non-participants (Appendix D) which gathered demographic data for 
those individuals opting out of the project. At the end of the project, all data from individual 





1. All participants will successfully reduce or discontinue use of benzodiazepines by the end of 
the pilot project. “Successful” reduction is defined as greater than fifty percent of pre-pilot 
dosage. 
2. All participants will demonstrate an acceptable level of distress while reducing 
benzodiazepine dosages throughout this pilot project as evidenced by less than a 4 point increase 
in GAD-7 scores from baseline scores. 
3. At least 75% of participants will report participation in the web-based program by the end of 
the project. 
Long-term Goal: 
The pilot project will be converted to usual practice standards within the entire CMHC by 
the end of one year, bringing the agency into compliance with established best practices for the 
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Resources and Costs 
 
            Expenses 




18-24 years 3% 
25-34 years 16% 
35-44 years 16% 
45-54 years 45% 
55-64 years 3% 









Single, Never Married 26% 
Married 15% 








African American/Black 19% 
Native American/American Indian 0 






Some High School/No Diploma 26% 
High School graduate/GED 39% 
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Employment Status 
Not Working/Looking 6% 
Not Working/Not Looking 81% 
Part-time 6% 
Full-time 6% 








Major Depression 44% 
Other Anxiety Disorders 22% 
Post-Traumatic Stress Disorder 19% 
Bipolar I Disorder 16% 
Attention Deficit Disorders 15% 
Generalized Anxiety Disorder 15% 
Panic Disorder 12% 
Obsessive-Compulsive Disorder 1% 
Bipolar II Disorder 1% 
Schizophrenia 1% 
Alcohol Use Disorders 1% 
Traumatic Brain Injury .03% 
Intellectual Disabilities .03% 
Mood Disorder NOS .03% 
Autism Spectrum Disorders .03% 
Intermittent Explosive Disorder .03% 
Anxiolytic Dependence .03% 
Schizoaffective Disorder .03% 






18-24 years 0 
25-34 years 0 
35-44 years 14% 
45-54 years 29% 
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55-64 years 43% 
65-74 years 0 







Single, Never Married 29% 
Married 29% 







African American/Black 14% 
Native American/American Indian 0 






Some High School/No Diploma 29% 
High School graduate/GED 43% 





Not Working/Looking 0 
Not Working/Not Looking 86% 
Part-time 14% 
Full-time 0 
>1 job 0 
 









Post-Traumatic Stress Disorder 51% 
Generalized Anxiety Disorder 43% 
Major Depression 29% 
Borderline Personality Disorder 29% 
Attention Deficit Disorders 14% 
Bipolar I Disorder 14% 
   
Results 
 
1) Goal: All participants will successfully reduce or discontinue use of benzodiazepines by the 
end of the pilot project. A “significant” reduction is deemed, by the project coordinator, to be 
at least 50%. 
Participant Beginning Benzo Dosage Ending Benzo Dosage % Decreased 
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Result: Four out of seven participants (57%) reduced their daily benzodiazepine dosage by 50% 
by the end of the project. All reduced their dosages in a range of 25-100%; the total average for 
the sample was 66%. Of note: all but one of these participants were taking clonazepam or 
diazepam, both agents have relatively long half-lives, especially diazepam. Patients, who engage 
in a tapering program on an agent such as alprazolam, may be especially prone to subjective 
withdrawal symptoms or rebound anxiety due the short half-life of that particular agent.  
2) Goal: All participants will demonstrate an acceptable level of distress while reducing 
benzodiazepine dosages throughout this pilot project as evidenced by less than a 4 point 
increase in GAD-7 scores from baseline scores. 














01 17 Severe 8 Mild Decrease 
02 16 Severe 16 Severe No Change 
03 19 Severe 21 Severe No Change 
04 13 Moderate 11 Moderate No Change 
05 21 Severe 8 Mild Decrease 
06 7 Mild 8 Mild No Change 
07 19 Severe 18 Severe No Change 
 
Result: All demonstrated an acceptable level of distress by the end of the project. Five out of the 
seven (71%) demonstrated no changes in their GAD-7 scores and 2 out of the seven (28%) 
showed a decrease in GAD-7 scores. 
3) Goal: At least 75% of participants will report participation in the web-based program by the 
end of the pilot project. 
Result: None of the participants used the web-based CBT program. 
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Control: 
The project controlled for therapy. 
Participant In Therapy at Beginning 
of project? 
In Therapy at End of 
project? 
Change in Frequency of 
sessions? 
01 Y Y N 
02 Y Y N 
03 Y Y N 
04 N N n/a 
05 N N n/a 
06 N N n/a 
07 Y N Y-stopped therapy 
 
There were no changes in active therapy status for 6 of the 7 (85%) participants. One 
participant stopped therapy during the project. (Of note is that that participant’s GAD-7 score did 
not change from pre- to post- project levels.) 
 As of August 2016, all participants in this project have remained active clients of the 
agency. All but one have completed their tapering programs successfully. The one remaining 
client is now on .5 mg clonazepam at bedtime with a goal to stop that dose at her next prescriber 
appointment. None of the participants have gone outside the agency for additional 
benzodiazepines, as evidenced by KASPER reports.  
Barriers and Solutions 
 One anticipated barrier was a potential for lack of competency and/or comfort on the 
patient’s part to engage in a web-based CBT program. Therefore, staff was available for 
rudimentary instruction and guidance in assuring that clients felt sufficiently competent in 
accessing the web-site. In this small sample population, no one used this tool so the resource was 
not needed, but for future implementation of these best practices, access to staff that is 
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knowledgeable and competent to assist clients with the tool as well as other CBT tools would be 
invaluable.  
 Another anticipated barrier was the reluctance of the patient to allow a reduction in 
benzodiazepines. While involvement in this project was voluntary, the onus was on the 
prescriber to provide education regarding the benefits of non-benzodiazepine treatment. Clients 
taking benzodiazepines are historically very reluctant to consider other forms of treatment and 
anticipatory anxiety increases when confronted with the possibility of “losing” the 
benzodiazepine.  
Resistance on the part of the prescriber could have been, and likely was, in this project, a 
barrier. Implementing change requires varying degrees of commitment both in terms of beliefs as 
well as a willingness to commit the time it takes to implement change, a willingness to consider 
change and a buy-in to the underlying belief that what one is doing is truly best. This may or may 
not have been a contributor to the absence of participants in the project other than the project 
coordinator’s clients. 
Not all the prescribers who expressed interest in this project and a willingness to 
participate work in the same setting. Thus their proximity to the project coordinator was limited. 
Even if a patient invited into the project voiced some interest, these prescribers did not have 
immediate access to the project coordinator to enlist that patient’s active involvement. Nor did 
the prescribers have the benefit of proximity to simply share in the day-to-day recruitment, 
sharing of knowledge and resources in order to enlist more active participants. 
Ethical considerations. As the only participants into this project came from the Project 
Coordinator’s caseload, it was incumbent on this prescriber to avoid coercion. Only clients for 
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whom this project coordinator was already tapering benzodiazepines were even invited into the 
project. Since the project coordinator had the “power” over prescribing these agents, it was 
deemed unethical to ask any client into the project who had not already consented to a tapering 
program months prior to the start of this pilot project. 
Unintended Consequences 
 The project coordinator anticipated that the participants would need some intervention 
added to their modalities of care to lessen the risk of increased anxiety, but none of the 
participants engaged in this program. In spite of that, there were no increases in overall anxiety. 
While the addition of another tool to manage anxiety during a tapering process may indeed be 
helpful, the lack of use of this program did not appear to impact these specific individuals. 
 One patient left treatment altogether subsequent to this tapering program. It is not clear if 
this medication change impacted that person’s decision to leave treatment as she simply dropped 
from care. 
 The use of the letter to invite clients into the project appears to have increased one 
person’s paranoia. The letter, sent to a client not under the care of the project coordinator, 
prompted him to bring the letter to discuss with his prescriber asking how and to whom his 
medical records had been released. When she explained that his name had been provided by her 
as an invitation to participate in the project, he actually verbalized an initial interest but later 
withdrew his name from consideration, offering no reason. So, in future studies, greater care 
should probably be taken to alert clients that they may be invited into a project before they are 
even approached.  
Recommendations 
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 It is recommended that the agency engage in an ongoing practice of educating 
prescribers, clinicians and clients in the best practices approach to the treatment of anxiety and 
work diligently to limit the use of benzodiazepines, if at all, to less than a few months as 
recommended by the literature. This project demonstrates, in a small way, that the perceived risk 
of an increase in anxiety once these agents are reduced and/or eliminated may not necessarily 
have a basis in fact or real experience.  
Group support has long been a staple of mental health services. The agency should 
consider developing groups for people with anxiety that are in various stages of benzodiazepine 
dependence to provide peer support through the process. 
 Changing a culture is time and energy intensive. Therefore, the staff need the support of 
the agency to allow these prescribers and staff to take the time needed to educate clients on the 
benefits of eliminating these agents and to provide additional tools and resources such as 
extended time with prescribers and more opportunities for individual and group therapies to 
support clients as they learn to manage their anxiety without the use of benzodiazepines. On 
possible solution to this may be the use of two-step appointments wherein the patient’s 
appointment with the therapist would precede the prescriber appointment. This would afford the 
patient the time and opportunity to work with a clinician on individual CBT or enable the patient 
time with the clinician to engage with a web-based CBT program and reinforce skills for self-
use.  
During the time this project was conceived, developed, and implemented, this agency 
began to work on a benzodiazepine cessation policy and procedure. The project coordinator was 
consulted periodically, regarding the progress and outcome of this project. The medical director 
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and assistant medical director consulted with the project coordinator throughout that planning 
process. On July 1, 2016, the agency adopted a policy that it would become benzodiazepine free  
and would begin tapering all benzodiazepines within the year. The policy also requires that no 
new prescriptions for benzodiazepines will be started by its prescribers after July 1, 2016.  The  
implementation of this policy, to date, appears to be going smoothly with minimal disruption to 









 Approvals were obtained from the Institutional Review Boards (IRB) of both Bellarmine 
University and Seven Counties Services before this pilot project was implemented. The 
Bellarmine University IRB is on file in the office of the Department Chair for the Doctorate in 
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Appendix B 
Living Life to the Fullest Web-site 
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Appendix C 
Project Demographics Master Data Collection Tool-Participants  
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Appendix D 
Project Demographics Master Data Collection Tool- Non-participants  
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